

Northern (NHS) Treatment Advisory Group

Treatment Appraisal: Decision Summary

Date	9 th April 2015
Appraisal & Details	<p>Lurasidone (Latuda®▼) for the treatment of schizophrenia in adults</p> <p>The Northern (NHS) Treatment Advisory Group considered an appraisal of Lurasidone (Sunovion Pharmaceuticals) for the treatment of schizophrenia.</p>
Recommendation	<p>The Northern (NHS) Treatment Advisory Group does not recommend the use of Lurasidone for treatment of schizophrenia.</p> <p>Clinical trial data shows that lurasidone is superior to placebo and non-inferior to quetiapine prolonged release for preventing relapse in adults with schizophrenia. However a place in therapy is difficult to ascertain as there is not sufficient comparative data to more established therapies. It is likely to compete with aripiprazole for use in patients in whom it is important to avoid weight gain and metabolic adverse effects. Aripiprazole has recently come off patent. Therefore further data showing advantages over aripiprazole are required before it can be recommended for use.</p>
Clinical evidence summary	<p>Evidence from five short-term and three long term (12 month) studies suggests that lurasidone is effective at treating psychotic symptoms, and in preventing relapse in adults with schizophrenia. However, in one of the studies (primarily a safety study) non-inferiority to risperidone was not demonstrated. The limited available data suggest that it may have some advantages over other antipsychotics for patients where weight gain or other metabolic disturbances are likely to have significant adverse consequences, although other adverse effects- including akathisia- may be more troublesome with lurasidone.</p>
Safety	<p>Lurasidone has a spectrum of adverse events that is similar to other second-generation antipsychotics. The SPC states that in clinical studies, the most common adverse events occurring in at least 1 in 10 participants were akathisia and somnolence which were dose-related up to 111 mg daily.</p>
Patient Perspective	<p>In the safety study against risperidone the rate of discontinuation due to all causes was statistically significantly higher in the lurasidone group compared with the risperidone group (64% compared with 52% respectively, $p=0.004$). The most common side effects of akathisia and somnolence can be difficult to manage.</p> <p>Patients need to avoid drinking grapefruit juice when taking lurasidone as it can increase serum concentration levels.</p>
Cost analysis summary	<p>The cost for 28 days' treatment with lurasidone at a dose of 37–148 mg daily is estimated to be £90.72 to £181.44. The cost for 28 days' treatment with alternative second-generation antipsychotics ranges from £0.97 to £194.56 depending on the drug and dose.</p> <p>However a generic version of aripiprazole has recently been launched in the UK and the NHS cost of aripiprazole is therefore falling.</p>
Financial impact	
PbR: In-tariff	<p>The financial impact of this recommendation is expected to be nil.</p>